NCT07660055 Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
| NCT ID | NCT07660055 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Novartis Pharmaceuticals |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 156 participants |
| Start Date | 2026-06-16 |
| Primary Completion | 2032-05-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 156 participants in total. It began in 2026-06-16 with a primary completion date of 2032-05-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of \[177Lu\]Lu-DWJ155 and the safety and imaging properties of \[68Ga\]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.
Eligibility Criteria
Inclusion Criteria: * Male or female patients age ≥ 18 years. * Patients with one of the following histologically or cytologically confirmed and documented malignancies who have progressed on or been intolerant to standard of care therapy, and are not considered appropriate for any standard therapy with proven benefit, in the investigator's judgment: * Dose Escalation: * Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting * Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced NSCLC without actionable genetic alterations (AGAs) with disease progression after prior therapy in the advanced setting * Advanced NSCLC with AGAs who have received prior treatment * Measurable disease as determined by RECIST version 1.1. * Dose Expansion: * Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting * Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR+/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR-/HER2-low breast cancer with disease progression after prior therapy in the advanced setting * Advanced HR-/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting * Advanced NSCLC with AGAs, who have received prior treatment * Advanced NSCLC without known AGAs who have received prior treatment. * Advanced gastric/GEJ cancer with HER2 IHC 3+ or 2+ (ISH + or -), following disease progression after prior therapy in the advanced setting * Advanced bladder cancer following disease progression after prior therapy in the advanced setting * Measurable disease as determined by RECIST version 1.1. Exclusion Criteria: * Out-of-range laboratory values defined as: * Creatinine clearance \< 60 mL/min (calculated using CKD-EPI 2021 formula, or measured) * Total bilirubin \> 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin \>3.0 x ULN) or direct bilirubin \> 1.5 x ULN * Alanine aminotransferase (ALT) \> 3 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT \> 5 x ULN * Aspartate aminotransferase (AST) \> 3 x ULN, except for patients with tumor involvement of the liver who are excluded if AST \> 5 x ULN * Lipase \> 1.5 x ULN * Absolute neutrophil count (ANC) \< 1.5 x 109/L * Hemoglobin \< 9 g/dL * Platelet count \< 100 x 109/L * Initiation of hematopoietic colony stimulating factors, thrombopoietin mimetics, or erythroid stimulating agents initiated ≤ 2 weeks prior to imaging agent administration. * Use of transfusion support ≤4 weeks prior to imaging agent administration. * Impaired cardiac function or clinically significant cardiac disease. * Unmanageable urinary tract obstruction or urinary incontinence. * Any serious uncontrolled infection (acute or chronic). * Pregnant or breastfeeding women. * Treatment with any of the following anti-cancer therapies prior to imaging agent administration within the stated timeframes: * Prior treatment with any therapeutic radiopharmaceutical * \< 10 half-lives for any imaging radiopharmaceutical * ≤ 4 weeks for external beam radiation therapy (EBRT) or brachytherapy * ≤ 6 months for lung-directed external beam radiotherapy * Patients with non-tumor uptake of \[68Ga\]Ga-DWJ155 in tissues or organs that, in the opinion of the investigator, increases the risk associated with \[177Lu\]Lu-DWJ155 treatment. Other protocol-defined inclusion/exclusion criteria may apply.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07660055 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07660055 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07660055 currently recruiting?
Yes, NCT07660055 is actively recruiting participants. Contact the research team at novartis.email@novartis.com for enrollment information.
Where is the NCT07660055 trial being conducted?
This trial is being conducted at Omaha, United States, New York, United States, Darlinghurst, Australia, Montreal, Canada and 2 additional locations.
Who is sponsoring the NCT07660055 clinical trial?
NCT07660055 is sponsored by Novartis Pharmaceuticals. The trial plans to enroll 156 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.